Loading...
•
Jul 01, 2023
Thermo Fisher Q2 2023 Earnings Report
Thermo Fisher's second quarter results were reported, showing a revenue decrease but strategic advancements.
Key Takeaways
Thermo Fisher Scientific reported a 3% decrease in revenue to $10.69 billion compared to the same quarter last year, with core organic revenue growth of 2%. GAAP diluted EPS was $3.51, and adjusted EPS was $5.15. The company revised its full-year guidance due to a challenging macroeconomic environment.
Revenue declined by 3% to $10.69 billion, with a 2% core organic revenue growth.
GAAP diluted EPS was reported at $3.51, while adjusted EPS reached $5.15.
The company launched innovative products, including the Thermo Scientific™ Orbitrap™ Astral™ mass spectrometer.
Thermo Fisher announced an agreement to acquire CorEvitas for approximately $0.9 billion, enhancing its clinical research business.
Revenue by Segment
Forward Guidance
Thermo Fisher revised its full-year revenue and adjusted EPS guidance due to the macroeconomic environment. The company now expects 2023 revenue to be in the range of $43.4 to $44.0 billion, with core organic revenue growth of 2 to 4%, and adjusted EPS of $22.28 to $22.72.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...